PCVX Latest Press Releases

-- December 8, 2025 --

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Globe Newswire 7:00 AM

-- November 4, 2025 --

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study Globe Newswire 4:05 PM

-- September 30, 2025 --

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services Globe Newswire 8:30 AM

Tentarix Biotherapeutics Strengthens Executive Team Business Wire 8:05 AM

-- September 3, 2025 --

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose Globe Newswire 7:30 AM

-- August 6, 2025 --

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software